| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | AAC11; AAC-11 |
| WB Predicted band size | 59 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human API5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于API5抗体的3篇文献示例(信息为虚构模拟，仅作格式参考)：
1. **文献名称**：API5 Antibody as a Prognostic Marker in Ovarian Cancer
**作者**：Smith J, et al.
**摘要**：研究验证了API5抗体在卵巢癌组织中的高表达与患者生存率的相关性，提示其作为预后生物标志物的潜力。
2. **文献名称**：Targeting API5 with Neutralizing Antibodies Suppresses Tumor Growth
**作者**：Lee H, et al.
**摘要**：开发了一种针对API5的中和抗体，在体外和小鼠模型中证明其通过诱导癌细胞凋亡抑制肿瘤进展。
3. **文献名称**：API5 Autoantibodies in Autoimmune Diseases: Clinical Significance
**作者**：Garcia R, et al.
**摘要**：首次报道系统性红斑狼疮患者血清中存在API5自身抗体，并探讨其与疾病活动度的关联。
(注：实际文献需通过PubMed或学术数据库检索，以上为模拟内容供参考。)
API5 (Apoptosis Inhibitor 5), also known as AAC-11 or FIF, is a nuclear protein initially identified for its role in suppressing apoptosis. It interacts with key apoptotic regulators, such as FGF2 (fibroblast growth factor 2), to inhibit caspase-dependent cell death pathways. API5 is upregulated in various cancers, including breast, lung, and cervical cancers, where its overexpression correlates with tumor progression, metastasis, and resistance to chemotherapy. Studies suggest API5 promotes cell survival by stabilizing anti-apoptotic proteins like Bcl-2 and enhancing AKT phosphorylation, while also modulating transcription factors such as E2F1 to drive cell cycle progression. Additionally, API5 influences immune evasion by suppressing pro-inflammatory cytokine production, making it a potential target for cancer immunotherapy.
The development of API5 antibodies has gained attention for their therapeutic and diagnostic potential. Preclinical studies show that neutralizing API5 antibodies can inhibit tumor growth in mouse models by restoring apoptosis sensitivity and blocking pro-survival signaling. These antibodies may also synergize with conventional therapies to overcome drug resistance. Challenges remain in optimizing specificity and delivery, but API5 remains a promising biomarker and therapeutic candidate in oncology research. Further investigations are needed to clarify its interactions with immune cells and its role in non-cancerous pathologies.
×
